Navigation Links
Typical IBD patients not represented in research studies
Date:8/22/2012

Major randomized controlled trials of new therapies for inflammatory bowel disease (IBD) are conducted on patients who are not typical of those who physicians see in day-to-day practice, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association (AGA).

The two major, often debilitating, illnesses that are recognized as IBD are ulcerative colitis and Crohn's disease. The introduction of biologics the most prescribed medications for IBD patients have dramatically impacted the ability to manage disease activity. However, a substantial percentage of IBD patients will have no response to these medications or lose response over time. This fact not only highlights the need for additional investigation of therapeutic targets, but also strategies to identify the optimal scenario for greatest therapeutic effect.

"Many outpatients with moderate-to-severe inflammatory bowel disease may not qualify for trials of new treatment options," said Christina Ha, MD, of the Johns Hopkins School of Medicine and lead author of this study. "Because of the heterogeneity of the inflammatory bowel disease patient population in terms of age of onset, disease behavior and severity, many patients may not meet the strict entry criteria for clinical trial participation. However, we often presume similar therapeutic effect among our clinic patients as demonstrated in clinical trials."

Researchers from the Johns Hopkins School of Medicine, Mount Sinai School of Medicine and Dartmouth-Hitchcock Medical Center performed a retrospective cohort study of 206 adult patients with moderate-to-severe IBD who went to the Mount Sinai Medical Center for an adjustment of their medical therapy from January 2008 to June 2009. Of these patients, only 31.1 percent would have been eligible to participate in a randomized controlled clinical trial of biologics. Reasons for exclusion included structuring or penetrating Crohn's disease, high-dose intake of steroids, comorbidities or prior exposure to biologics, or treatment with topical therapies.

Results from randomized clinical trials form the basis for FDA approval of treatments, expert recommendations and guidelines for the management of IBD patients, and are currently the best approach available to study treatment effects. However, by limiting the available pool of potential study patients through strict inclusion and exclusion criteria in an effort to maximize clinical trial results, these trial results may have limited applicability in the real-world doctor's office.

In addition, limiting selection criteria requires larger study populations, longer durations of follow-up observation and substantially greater cost. However, shifting to a more pragmatic-based approach with minimal study exclusions may help physicians generalize study results to their day-to-day practice as well as support randomized controlled trial findings in a more common clinical practice setting.


'/>"/>
Contact: Alissa J. Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. MR enterography is option for pediatric patients with Crohn disease
2. 2 Tests May Improve Heart Patients Care, Studies Suggest
3. Doctors Who Self-Refer to Radiation Clinics Add to Patients Burden: Study
4. Breast density does not influence breast cancer death among breast cancer patients
5. Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients
6. Scientists to investigate preventing life-threatening complications in transplant patients
7. New Drug Appears to Extend Survival in Advanced Prostate Cancer Patients
8. Pre-test genetic counseling increases cancer knowledge for BRCA patients
9. Urology-owned radiation oncology self-referral can increase patients travel distance for treatment
10. Nurses as effective as doctors in treatment of HIV patients
11. Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Los Angeles, CA (PRWEB) , ... March 23, 2017 , ... ... half of all Americans, yet poor sleep is likely not the only cause of ... these undesirable characteristics that make you look older or in poor health are likely ...
(Date:3/23/2017)... ... 23, 2017 , ... Corra Group is now offering exclusively ... Verisys through its FACIS and other services maintains the largest healthcare database ... are delighted to be able to offer these various products to our healthcare ...
(Date:3/23/2017)... McKinney, Texas (PRWEB) , ... March 23, 2017 ... ... Operations Command (USSOCOM) awarded Task Force Dagger Foundation the US Special Operations Command’s ... Thomas. During the presentation, General Thomas thanked Task Force Dagger Foundation for its ...
(Date:3/23/2017)... DC (PRWEB) , ... March 23, 2017 , ... News ... Dental Choice has helped score a major victory in Europe for public health and ... , Based on rigorous scientific research and the overwhelming support of European ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... an innovative patient - centric payment system, to expand its focus on patient ... the patient financial experience. , “At Ogden Clinic, we are working to ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 Under ... Chinese pharmaceutical packaging market size increased year by ... From 2017 to 2021, the market size will ... is expected to outnumber RMB140 billion in 2021, ... the rapid development of biological agents and supporting ...
(Date:3/22/2017)... Pennsylvania , 22. März 2017 /PRNewswire/ ... unabhängige und weltweit tätige Anbieter von Produkten ... heute den Erwerb von EPL Archives Inc. ... Stoffe, der Kunden im kompletten Zyklus regulierter ... Verwahrung von Proben, Speicherung von Dokumenten und ...
(Date:3/22/2017)... 22, 2017  Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced the latest line-up ... 2017 is a day full of presentations, posters, ... (QSP) community. The focus is to learn about ... accelerating drug research and development. The ...
Breaking Medicine Technology: